Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology

Company Overview - Trinity Biotech plc is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors [6] - The company develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory segments [6] - Recently, Trinity Biotech entered the wearable biosensor industry through the acquisition of biosensor assets from Waveform Technologies Inc. [6] Technology Development - Trinity Biotech has developed a glucose biosensor technology and was granted a European patent (EP3703565) for a novel method that enhances the performance of indwelling sensors [1][3] - The patented process significantly reduces the "run-in" or "settling" period for continuous glucose monitors (CGMs), enabling reliable glucose measurements more quickly [3] - The conditioning process has shown improvements in the accuracy of the device compared to laboratory reference methods, enhancing the Mean Absolute Relative Difference (MARD) [3] Product Advancements - The Chief Technology Officer, Dr. Gary Keating, highlighted that the patented technology represents a major advancement for the CGM platform, aiming for a more user-friendly, fully self-calibrating device [4] - The CGM technology acquired in January is noted for its affordability and sustainability due to its unique self-inserted biosensor wire [4] - Upcoming pre-pivotal trials will further evaluate the effectiveness of the conditioning process and other refinements to the biosensor wire design [4] Market Context - Continuous glucose monitors (CGMs) are increasingly popular in diabetes management and health monitoring, utilizing biosensor wires under the skin to measure glucose in real-time [2] - The advancements in CGM technology are expected to enhance market acceptance and penetration of Trinity Biotech's products [5]